Early Translational III

Return to Grants

RFA 11-02 CIRM Early Translational III Research Awards 

The CIRM Early Translational Research Initiative aims to fund and advance innovative translational stem cell science toward clinical development. The purpose of this CIRM Early Translational III Research Awards RFA is to support projects that enable the initial stage of translational research including the conduct of studies resulting in proof of concept for a potential development candidate and/or studies to select a Development Candidate (DC). The Early Translational Research Award is core to CIRM’s mission, and the agency plans to issue this RFA every one to two years to build a strong preclinical pipeline for patient therapies and cures.

This RFA includes participation by members of CIRM’s Collaborative Funding Partner Program. The CIRM Loan Program is also included in this RFA.

Please see the full RFA for details:
RFA 11-02: CIRM Early Translational III Research Awards [pdf]

Appendix A: Examples: In-Scope Research Activities, Milestones and Success Criteria
Appendix B: CIRM’s Translational Portfolio
Appendix C:CIRM Loan Terms
Appendix D: National Health and Medical Research Council (NHMRC) in Australia
Appendix E: Japan Science and Technology Agency (JST)
Appendix F: German Federal Ministry for Education and Research (BMBF)
Appendix G: Ministry of Science and Technology of the People’s Republic of China (MOST)

Application Process

Submission of an application for the CIRM Early Translation III RFA involves a two-step process. An eligible PI may submit one Preliminary Application (PreApp). PreApps will be evaluated by scientific specialists from outside California who are experts in specific areas of research described in the PreApp and by CIRM scientific staff, based on the scientific review criteria described in section IX of this RFA. Applicants whose projects are judged as most promising, competitive, and responsive to the RFA will be invited to submit a full application. All other applicants will be deferred, with the opportunity to apply in response to a future RFA.

Preliminary Application (PreApp) Instructions

The web-based PreApp proposal will be made available on June 30, 2011 through the CIRM Grants Management Portal at https://grants.cirm.ca.gov. All PreApps must be submitted online through the CIRM Grants Management Portal.

Each PI may submit only a single PreApp for this RFA.

The deadline for submission is 5:00 pm (PDT) on Aug 10, 2011. No exceptions to this deadline will be made.

To submit a Preliminary Application:
1. Go to the Grants Management Portal (https://grants.cirm.ca.gov) and log in with your existing CIRM Username and Password. If you do not have a Username, click on the “New User” link and follow the instructions to create a CIRM Username and password.

2. After logging in, your home page will display a list of open RFAs. Click on the “Start a PreApp” link corresponding to the Early Translation III RFA.

3. Complete each section by clicking on the appropriate link and following the posted instructions. Once the online proposal sections have been completed, you may download, fill out and submit the signature page and Related Business Entities (if applicable) templates through the “Upload Required Documents” section.

4. The “Done with Preliminary Application” button becomes enabled when all sections are complete and all required documents have been uploaded. Once “Done with Preliminary Application” has been selected, you will no longer be able to make changes to your PreApp.

5. To ensure the process is complete, go back to your home page and check the list under “Your Preliminary Applications“. The status for Early Translational III should be “Submitted“.

Full Application Process

Full Applications will only be accepted from applicants who 1) submitted a PreApp and 2) are invited by CIRM to submit a full application.

The application for the CIRM Early Translational Awards III RFA consists of four parts:

Part A: Application Information Form (Web-based form)
Part B: Proposal (MS Word template)
Part C: Biographical Sketches and Letters of Support (MS Word template)
Part D: Related Business Entities Disclosure Form (Adobe PDF template)

All four parts of the full Application for CIRM Early Translation III must be submitted together and received by CIRM no later than 5:00 pm (PST) on December 15, 2011, in both electronic form and in hard copy (a signed original and five copies). It is the applicant’s responsibility to meet this deadline; no exceptions will be made.

You will need a fully functional copy of Adobe Acrobat version 8 or 9 (Standard or Professional) to complete, print, and save Parts D of the full Application. We recommend using Adobe Acrobat version 8.1 (or the latest version). Using Adobe Acrobat Reader will not permit you to save information that is entered in the form.

Schedule of CIRM deadlines and reviews Date
Pre-Applications due  5:00 pm (PDT), August 10, 2011
Invitations for full Applications sent out by CIRM October 28, 2011
Full Applications due 5:00 pm (PST), December 15, 2011
Review of full Applications by Grants Working Group (GWG)  March, 2012
Review and Approval by ICOC May, 2012
Earliest Funding of Awards Summer, 2012






No exceptions will be made to the indicated deadlines.


For information about this RFA or the review process:

Gilberto R Sambrano, Ph.D
Senior Review Officer
California Institute for Regenerative Medicine
Email: gsambrano@cirm.ca.gov
Phone: (415) 396-9103

ICOC Approval:
May 24, 2012
Total Awards:
Award Value:


Institution Investigator Grant Title Award Value
Salk Institute for Biological Studies Dr. David R Schubert Stem cell based small molecule therapy for Alzheimer’s disease $1,673,757
City of Hope, Beckman Research Institute Dr. Stephen J Forman Targeting glioma cancer stem cells with receptor-engineered self-renewing memory T cells $5,215,447
Gladstone Institutes, J. David Dr. Deepak Srivastava Direct Cardiac Reprogramming for Heart Regeneration $5,795,871
University of California, San Diego Dr. Lawrence S. B. Goldstein Identifying Drugs for Alzheimer’s Disease with Human Neurons Made From Human IPS cells $1,774,420
University of California, San Diego Dr. Yang Xu Human ES cell based therapy of heart failure without allogenic immune rejection $1,857,600
Stanford University Dr. Joseph C. Wu Heart Repair with Human Tissue Engineered Myocardium $4,395,080
University of California, San Francisco Mort Cowan Gene Correction of Autologous Hematopoietic Stem Cells in Artemis Deficient SCID $3,862,367
Stanford University Professor Helen M. Blau PhD Local Delivery of Rejuvenated Old Muscle Stem Cells to Increase Strength in Aged Patients $1,825,283
University of Southern California Dr. Toshio Miki Generation of hepatic cell from placental stem cell for congenital metabolic disorders $1,750,375
Children’s Hospital of Orange County Dr. Philip H Schwartz Immune-Matched Neural Stem Cell Transplantation for Pediatric Neurodegenerative Disease $4,266,015
University of California, San Francisco Dr. Holger F Willenbring Generation of safe and therapeutically effective human induced hepatocyte-like cells $1,544,170
Salk Institute for Biological Studies Juan Carlos Izpisua Belmonte Direct reprogramming towards vascular progenitors for the treatment of ischemia $2,340,000
University of California, San Diego Dr. Eric D. Adler MD Identification of Novel Therapeutics for Danon Disease Using an iPS Model of the Disease $1,701,575
University of California, Davis Walter Douglas Boyd Extracellular Matrix Bioscaffold Augmented with Human Stem Cells for Cardiovascular Repair $4,631,754
Stanford University Dr. Bertha Chen Autologous iPSC Therapy for Urinary Incontinence $4,715,738
University of California, San Diego Mark H Tuszynski Functional Neural Relay Formation by Human Neural Stem Cell Grafting in Spinal Cord Injury $4,600,447
University of California, Davis Prof. Kyriacos A. Athanasiou Ph.D Tissue engineered cartilage from autologous, dermis-isolated, adult, stem (DIAS) cells $1,735,703
University of California, Irvine Craig M. Walsh Multiple Sclerosis therapy: Human Pluripotent Stem Cell-Derived Neural Progenitor Cells $4,535,005
Scripps Research Institute Peter G. Schultz Targeting Stem Cells to Enhance Remyelination in the Treatment of Multiple Sclerosis $2,559,333
University of California, San Francisco Dr. Arnold Kriegstein Human ES cell-derived MGE inhibitory interneuron transplantation for spinal cord injury $1,623,251
University of California, San Diego Gene Wei-Ming Yeo Molecules to Correct Aberrant RNA Signature in Human Diseased Neurons $1,532,323